Pharmacy News Article

19 November 2009 - Canadian clinical-stage biotechnology company Aegera Therapeutics Inc said today it has started dosing of the first patient in a randomised Phase IIb study of AEG35156, a targeted antisense therapeutic in mid-stage development for multiple oncology indications.

The study, entitled "An Open-Label Randomised Phase II Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 Given in Combination with High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen", is being conducted in the United States and Canada and will also be conducted in Germany, subject to final regulatory approval.

This clinical trial follows shortly after the completion of the company's first Phase II clinical trial in this indication, the results of which were recently reported in the Journal for Clinical Oncology.

((Comments on this story may be sent to tww.feedback@m2.com))